Paradigm Biopharmaceuticals (ASX:PAR) will proceed with a phase 3 knee osteoarthritis trial of Zilosul, following a 30-day review by the US Food and Drug Administration of its clinical trial protocol, according to a Thursday filing with the Australian bourse.
The study's primary endpoint is a change from baseline in pain using injectable pentosan polysulfate sodium, with changes in the Patient's Global Impression of Pain, functional assessments at specific time points, and structural changes as secondary endpoints, the filing said.
Patient enrollment will start in the first quarter of next year at 10 Australian clinical trial sites, followed by US sites, as per the filing.
The company's shares tumbled almost 14% in recent Thursday trade.
Price (AUD): $0.50, Change: $-0.08, Percent Change: -13.91%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.